2-(4-羟基-1-哌啶基)苯甲醛 | 291545-00-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-(4-羟基-1-哌啶基)苯甲醛
• 英文名称: 2-(4-Hydroxypiperidino)benzaldehyd
• 英文别名: 2-(4-Hydroxypiperidin-1-yl)benzaldehyde
• CAS: 291545-00-1
• 化学式: C₁₂H₁₅NO₂
• 分子量: 205.257
• InChiKey: IOZXWZKDOMWEAG-UHFFFAOYSA-N

物化性质

• 沸点：
  379.5±37.0 °C(Predicted)
• 密度：
  1.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-羟基-1-哌啶基)苯甲醛 在 lithium aluminium tetrahydride 、 EDTA di-sodium salt dihydrate 、 mercury(II) oxide 作用下， 以 乙醚 、 水 为溶剂， 反应 0.25h， 生成 4-Hydroxy-1-(2-hydroxymethylphenyl)piperidin-2-on
  参考文献：
  名称：

  Moehrle; Jeandree; Breitmaier, Advanced Synthesis and Catalysis, 2000, vol. 342, # 5, p. 473 - 485

  摘要：

  DOI：
• 作为产物：
  描述：

  4-羟基哌啶 、 2-氟苯甲醛 在 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 以47%的产率得到2-(4-羟基-1-哌啶基)苯甲醛
  参考文献：
  名称：

  Moehrle; Jeandree; Breitmaier, Advanced Synthesis and Catalysis, 2000, vol. 342, # 5, p. 473 - 485

  摘要：

  DOI：

文献信息

• [EN] MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS<br/>[FR] COMPOSES INHIBANT LA PROTEINE KINASE-2 ACTIVEE PAR LA PROTEINE KINASE ACTIVEE PAR DES AGENTS MITOGENES
  申请人：PHARMACIA CORP

  公开号：WO2004058762A1

  公开（公告）日：2004-07-15

  Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of using such compounds for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNFα, are described, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Therapeutic compositions, pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.

  本文描述了抑制有丝分裂原活化蛋白激酶激活蛋白激酶2（MK-2）的化合物。描述了使用这些化合物来抑制MK-2，以及预防或治疗由TNFα介导的疾病或障碍的方法，其中该方法涉及向受试者施用本发明的MK-2抑制剂化合物。还描述了包含本MK-2抑制剂化合物的治疗组合物、药物组合物和试剂盒。
• Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
  申请人：Pharmacia Corporation

  公开号：US20040209897A1

  公开（公告）日：2004-10-21

  Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of using such compounds for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNF&agr;, are described, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Therapeutic compositions, pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.

  本文描述了抑制有丝分裂原活化蛋白激酶激活蛋白激酶-2（MK-2）的化合物。本文还描述了使用这些化合物来抑制MK-2并预防或治疗由TNFα介导的疾病或障碍的方法，其中该方法涉及向受试者施用本发明的MK-2抑制化合物。本文还描述了包含本MK-2抑制化合物的治疗组合物、制药组合物和试剂盒。
• Linear addition polymer with hyperpolarizable side groups
  申请人：Akzo Nobel N.V.

  公开号：EP0290061A1

  公开（公告）日：1988-11-09

  A linear addition polymer having sidegroups which may be coupled to it or not through a spacer and have a molecular hyperpolarizability β of at least 10⁻³⁸ m⁴/V, characterized in that the recurring units of the polymer correspond to the formula wherein X represents a hydrogen atom or a lower alkyl group and m = 1 or optionally 0, where when m = 1 Y represents a group and R has the meaning of a) a hyperpolarizable group having a molecular hyperpolarizability β of at least 10⁻³⁸ m⁴/V, in the presence or not of a spacer, and optionally along with b) a mesogenic group in the presence or not of a spacer, and/or c) a hydrogen atom or a substituted or unsubstituted organic group having not more than 30 carbon atoms, and when m = 0 Y represents a -CN, a substituted or unsubstituted phenyl group or a group of the formula -OR₁ or -CH₂OR₁, wherein R₁ has the meaning of a hydrogen atom or a substituted or unsubstituted aliphatic group having not more than 20 carbon atoms, provided that - at least 10% of the recurring units in the polymer contain a hyper­polarizable group having a molecular hyperpolarizability β of at least 10⁻³⁸ m⁴/V, - at the most 40% of the recurring units in the polymer contain a mesogenic group, and - that the quotient of the degree of substitution of the recurring units with a group having a molecular hyperpolarizability β of at least 10⁻³⁸ m⁴/V and the average molecular weight of R with the meaning given under b and c amounts to at least 5 × 10⁻⁴, a non-linear optical medium thereof oriented in an electric field and electro-optical laminates com­prising such a non-linear optical medium.

  一种具有侧基的线性加成聚合物，侧基可通过或不通过间隔物与之连接，其分子超极化率 β 至少为 10-³⁸ m⁴/V，其特征在于该聚合物的循环单元符合以下式子 其中 X 代表氢原子或低级烷基，m = 1 或可选 0，其中 当 m = 1 时 Y 代表一个 基团，R 的含义为 a) 分子超极化率 β 至少为 10-³⁸ m⁴/V 的可超极化基团，无论是否存在间隔物，并可选择连同 b) 介原基团（无论有无间隔物），和/或 c) 氢原子或碳原子数不超过 30 个的取代或未取代的有机基团，以及 当 m = 0 时 Y 代表-CN、取代或未取代的苯基或式-OR₁或-CH₂OR₁的基团，其中 R₁ 的含义是氢原子或碳原子数不超过 20 个的取代或未取代的脂肪族基团、 条件是 - 聚合物中至少 10%的重复单元含有可超极化的基团，其分子超极化率 β 至少为 10-³⁸ m⁴/V、 - 聚合物中最多有 40%的重复单元含有介原基，且 - 循环单元与分子超极化率 β 至少为 10-³⁸ m⁴/V 的基团的取代度与具有 b 和 c 项中所述含义的 R 的平均分子量的商至少为 5 × 10-⁴。
• Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists
  作者：Pramod Joshi、Corey Anderson、Hayley Binch、Sabine Hadida、Sanghee Yoo、Danielle Bergeron、Caroline Decker、Ernst terHaar、Jonathan Moore、Miguel Garcia-Guzman、Andreas Termin

  DOI：10.1016/j.bmcl.2013.12.089

  日期：2014.2

  Calcitonin gene-related peptide (CGRP) has been implicated in acute migraine pathogenesis. In an effort to identify novel CGRP receptor antagonists for the treatment of migraine, we have discovered thiazolidinone 49, a potent (K-i = 30 pM, IC50 = 1 nM), orally bioavailable, CNS-penetrant CGRP antagonist with good pharmacokinetic properties. (C) 2013 Elsevier Ltd. All rights reserved.
• MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS
  申请人：Pharmacia Corporation

  公开号：EP1572693A1

  公开（公告）日：2005-09-14